We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

60 hedge funds and large institutions have $264M invested in Paratek Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

12% less funds holding

Funds holding: 6860 (-8)

24% less capital invested

Capital invested by funds: $346M → $264M (-$82.6M)

62% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 13

Holders
60
Holders Change
-8
Holders Change %
-11.76%
% of All Funds
1.68%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
5
Increased
22
Reduced
18
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$45.8M
OFM
2
Omega Fund Management
Massachusetts
$40.6M
BG
3
Baupost Group
Massachusetts
$29.3M
A
4
Abingworth
United Kingdom
$24.7M
TCM
5
Tekla Capital Management
Massachusetts
$14.5M +$1.78M +71,581 +10%
AC
6
Aisling Capital
New York
$13M
BC
7
Broadfin Capital
New York
$10.1M
GPP
8
Great Point Partners
Connecticut
$8.62M +$960K +38,540 +9%
BBHC
9
Brown Brothers Harriman & Co
New York
$6.99M
GIM
10
Granahan Investment Management
Massachusetts
$6.46M +$4.96M +198,912 +141%
Vanguard Group
11
Vanguard Group
Pennsylvania
$6.35M +$596K +23,922 +8%
BFA
12
BlackRock Fund Advisors
California
$6M -$78.6K -3,156 -1%
Jennison Associates
13
Jennison Associates
New York
$5.76M +$38.2K +1,534 +0.5%
GAI
14
General American Investors
New York
$5.26M
Bank of New York Mellon
15
Bank of New York Mellon
New York
$4.37M -$135K -5,428 -2%
JP Morgan Chase
16
JP Morgan Chase
New York
$4.12M +$2.87K +115 +0.1%
RAM
17
Roumell Asset Management
Maryland
$3.83M -$146K -5,858 -3%
OA
18
Omega Advisors
New York
$2.7M +$44.9K +1,800 +1%
State Street
19
State Street
Massachusetts
$2.65M +$838K +33,631 +32%
LOAMU
20
Lombard Odier Asset Management (USA)
New York
$2.58M -$107K -4,290 -3%
BIT
21
BlackRock Institutional Trust
California
$2.38M +$918K +36,827 +42%
NMC
22
NEA Management Company
Maryland
$2.38M -$1.22M -48,888 -28%
Northern Trust
23
Northern Trust
Illinois
$2.37M +$2.64M +106,096 +564%
SM
24
Sabby Management
Florida
$2.22M +$1.53M +61,433 +110%
Renaissance Technologies
25
Renaissance Technologies
New York
$1.88M -$131K -5,273 -5%

PRTK Hedge Fund Activity: Q3 2015 in Review

60 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2015, worth a combined $264M — down 24% from $346M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRTK and 5 opened new positions — a net loss of 8 holders — while 18 trimmed existing stakes and 22 added.

The largest buyer was Granahan Investment Management, adding an estimated $4.96M. The largest seller was NEA Management Company, cutting an estimated $1.22M.

  • 60 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2015, down from 68 in Q2 2015.
  • Funds reported $264M of Paratek Pharmaceuticals, Inc. stock for Q3 2015, down 24% quarter-over-quarter.
  • 5 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2015 and 13 closed out, a net change of -8 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2015 was Granahan Investment Management, an estimated $4.96M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q3 2015 was NEA Management Company, an estimated $1.22M sold.

Based on aggregated 13F filings for Q3 2015.